All Stories

  1. Unraveling the CFTR Function–Phenotype Connection for Precision Treatment in Cystic Fibrosis
  2. Highlights from the 2017 North American Cystic Fibrosis Conference
  3. Airway microbiota across age and disease spectrum in cystic fibrosis
  4. Highlights from the 2016 North American Cystic Fibrosis Conference
  5. Alterations of the Nasopharyngeal Microbiota in Infants with Cystic Fibrosis. Cystic Fibrosis Transmembrane Conductance Regulator and Antibiotic Effects
  6. Cholesteryl Esters Are Elevated in the Lipid Fraction of Bronchoalveolar Lavage Fluid Collected from Pediatric Cystic Fibrosis Patients
  7. Intestinal Lesions Are Associated with Altered Intestinal Microbiome and Are More Frequent in Children and Young Adults with Cystic Fibrosis and Cirrhosis
  8. Assessment of Airway Microbiota and Inflammation in Cystic Fibrosis Using Multiple Sampling Methods
  9. Sputum induction improves detection of pathogens in children with cystic fibrosis
  10. Narrowing in on Early Cystic Fibrosis Lung Disease
  11. Advances in the Diagnosis and Treatment of Cystic Fibrosis
  12. Cystic Fibrosis Transmembrane Conductance Regulator andPseudomonas
  13. Clinical outcomes after initialpseudomonasacquisition in cystic fibrosis
  14. The Human Airway Microbiome
  15. Microbes in Bronchiectasis: The Forest or the Trees?
  16. Inflammation and Airway Microbiota during Cystic Fibrosis Pulmonary Exacerbations
  17. Sputum Biomarkers of Inflammation and Lung Function Decline in Children with Cystic Fibrosis
  18. Newborn screening for cystic fibrosis
  19. The airway microbiome in cystic fibrosis and implications for treatment
  20. Anaerobic Bacteria As Biomarkers Of Lung Function Decline In Cystic Fibrosis
  21. Clinical Value Of Sputum Induction To Diagnose Infection In Cystic Fibrosis
  22. Chronic cough
  23. Evaluation of cough and pulmonary disorders
  24. Reliability of Quantitative Real-Time PCR for Bacterial Detection in Cystic Fibrosis Airway Specimens
  25. Measuring and improving respiratory outcomes in cystic fibrosis lung disease: Opportunities and challenges to therapy
  26. Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures